CEMEDIUM SIGNALFINANCIAL10-K

CE reduced workforce by 6% while posting continued operating losses despite improved cash generation and reduced capital spending.

The company appears to be implementing cost reduction measures including workforce reductions and lower capital expenditures, which helped improve operating cash flow generation. However, the business remains unprofitable at the operating level, and the decline in stockholders' equity suggests ongoing financial pressure that investors should monitor closely.

Comparing 2026-02-24 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

CE showed mixed financial performance with net losses narrowing modestly while gross profit declined meaningfully and operating losses deepened slightly. The company generated improved operating cash flow while reducing capital expenditures by over 20%, suggesting a focus on cash preservation. However, the decline in stockholders' equity and continued operating losses indicate underlying business challenges that offset the improved cash generation.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+23.5%
-$1.5B-$1.2B

Net income grew 23.5% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-21.8%
$5.2B$4.0B

Equity decreased 21.8% — buybacks or losses reducing book value, monitor solvency ratios.

Capital Expenditure
Cash Flow
-21.1%
$435.0M$343.0M

Capex reduced 21.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+18.6%
$966.0M$1.1B

Operating cash flow grew 18.6% — strong conversion of earnings to cash, healthy business fundamentals.

Accounts Receivable
Balance Sheet
-17.8%
$1.1B$922.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-17.1%
$2.4B$2.0B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Income
P&L
-12.8%
-$697.0M-$786.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

SG&A Expense
P&L
-12.7%
$1.0B$899.0M

SG&A reduced 12.7% — improved cost efficiency or headcount reduction improving operating margins.

Current Assets
Balance Sheet
+10.7%
$5.1B$5.7B

Current assets grew 10.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-21
ADDED
The number of outstanding shares of the registrant's common stock, $0.0001 par value, as of February 20, 2026 was 109,571,972 .
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.
As of December 31, 2025, we employed 11,434 people worldwide.
These global trends drive a range of needed customer solutions, such as vehicle lightweighting, precise components, aesthetics and appearance, low emissions, heat resistance and low-friction for medical applications, that we are uniquely positioned to address with our materials portfolio.
Our nylon products include Celanyl (PA6, PA6.6), FRIANYL (flame retardant PA6, PA66, PPA compounds), ECOMID (recycled polyamide), Zytel (PA, PA6, PA66, PA610, PA612), Zytel high temperature nylons, (PPA) and Zytel long-chain polyamides and are used in automotive, appliances, electrical, medical, industrial and consumer applications due to their mechanical properties, dimensional stability, high impact resistance, resistance to organic solvents, high wear and fatigue resistance even at high temperatures, and easy processing and molding.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant's common stock, $0.0001 par value, as of February 17, 2025 was 109,332,326 .
Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 7A.
As of December 31, 2024, we employed 12,163 people worldwide.
Ascend Performance Materials LLC BASF SE Daicel Corporation ("Daicel") DOMO Chemicals Kingfa Science and Technology Korea Petrochemical Ind.
Co, Ltd ("KPIC") Envalior GmbH SABIC Innovative Plastics Solvay S.A.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →